8-K: VitaNova Life Sciences Emerges with Reverse Split, New Preferred Stock

Yijia Group Corp. announced a corporate rebranding to VitaNova Life Sciences Corporation, a 1-for-3 reverse stock split, and the designation of Series A Preferred Stock.

Summary

• The company's name officially changed from Yijia Group Corp. to VitaNova Life Sciences Corporation, effective January 9, 2026.
• A 1-for-3 reverse stock split was approved and became effective on January 9, 2026, meaning each three shares of common stock will convert into one new share.
• The total authorized capital stock increased to 210,000,000 shares, comprising 200,000,000 shares of Common Stock and 10,000,000 shares of initially undesignated Preferred Stock, effective November 12, 2025.
• 3,000,000 shares of the authorized Preferred Stock were designated as Series A Preferred Stock, effective November 21, 2025.
• Series A Preferred Stock holders receive 20 votes per share, voting with common stock as a single class, and have protective voting rights for adverse changes to their preferences.
• Each Series A Preferred Stock share is convertible at the holder's option into one share of Common Stock.
• Series A Preferred Stock does not participate in dividends or liquidation distributions.
• A scriveners error in the par value of common stock was corrected from $0.0001 to $0.001 per share on November 21, 2025.
• A new CUSIP number (98585W403) has been obtained for the Common Stock.
• The company intends to change its ticker symbol, currently YJGJ on OTC Pink Sheets, and is evaluating potential new symbols.

Sentiment

Score: 4

Explanation: The corporate rebranding and increased authorized shares offer potential for future growth and strategic flexibility. However, the reverse stock split often carries a negative market perception, and the preferred stock structure concentrates voting power, which could be viewed unfavorably by common shareholders. The pending FINRA approvals also introduce uncertainty.

Positives

• Corporate rebranding to VitaNova Life Sciences Corporation may signal a new strategic direction or focus, potentially attracting new investors.
• The reverse stock split could increase the per-share price, potentially improving market perception and meeting exchange listing requirements.
• The creation of Series A Preferred Stock with significant voting power (20 votes per share) allows for strategic control and potential future capital raises from specific investors.
• The optional conversion feature of Series A Preferred Stock provides flexibility for holders to convert to common stock.
• Increased authorized shares provide flexibility for future capital raises, acquisitions, or employee incentive plans.

Negatives

• Reverse stock splits are often viewed negatively by the market as they can indicate a company's struggle to maintain a higher share price or meet listing requirements.
• Series A Preferred Stock holders do not participate in dividends or liquidation distributions, which might be a negative for those specific investors if they were seeking income or liquidation preference.
• The significant voting power of Series A Preferred Stock (20 votes per share) could dilute the voting influence of common stockholders.
• FINRA is still processing the name change and reverse split, indicating that these changes are not fully reflected in the market yet.

Risks

• FINRA is still processing the Name Change and Reverse Split, which could lead to delays in market reflection of these corporate actions.
• The Corporation must take corporate action to increase authorized common stock if the current number is insufficient to effect conversion of all outstanding Series A Preferred Stock, including obtaining requisite stockholder approval.
• Any amendment to the Certificate of Designation that would adversely alter Series A Preferred Stock rights requires majority consent from Series A holders, potentially limiting future corporate flexibility.

Future Outlook

The company is awaiting FINRA processing for both the name change and the reverse stock split. It also intends to change its ticker symbol and is currently evaluating potential new symbols.

Management Comments

• The Board of Directors and a majority of stockholders approved the name change to VitaNova Life Sciences Corporation.
• The Board of Directors and a majority of stockholders approved a reverse stock split at a ratio within the range from 1-for-2 to 1-for-3, with the Board subsequently approving a 1-for-3 ratio.
• The Board of Directors and a majority of stockholders approved the increase in authorized shares and the authorization of blank check preferred stock.
• The Board of Directors and a majority of stockholders approved the designation of 3,000,000 shares as Series A Preferred Stock.

Industry Context

Corporate rebranding, reverse stock splits, and the issuance of preferred stock are common strategies for companies seeking to reposition themselves, improve stock liquidity, or attract strategic investors. A reverse split often aims to increase the per-share price, potentially to meet exchange listing requirements or improve investor perception, though it does not change the company's overall market capitalization. The creation of a new preferred stock series with significant voting rights suggests a strategic move to consolidate control or provide specific incentives to certain investors, which is typical in growth-oriented or restructuring phases.

Comparison to Industry Standards

• Reverse stock splits are common among companies trading at low share prices, often to avoid delisting or to make the stock more attractive to institutional investors. For example, companies like General Electric (GE) and Citigroup (C) have executed reverse splits in the past to consolidate shares and improve per-share value.
• The designation of preferred stock with enhanced voting rights but no dividend or liquidation preference is often seen in private equity or venture capital investments, where control and future conversion potential are prioritized over immediate income or liquidation priority. This structure is less common for publicly traded preferred stock, which typically offers dividend income or liquidation preference.
• The 20-to-1 voting ratio for Series A Preferred Stock is a significant control mechanism, comparable to dual-class share structures seen in tech giants like Google (Alphabet) or Meta (Facebook), where founders or early investors retain disproportionate voting power.

Corporate Governance

Stakeholder Impact

• Shareholders (Common Stock): Experience a 1-for-3 reverse stock split, consolidating their shares and increasing the per-share price. Their voting power may be diluted by the introduction of Series A Preferred Stock with 20 votes per share.
• Shareholders (Series A Preferred Stock): Gain significant voting control (20 votes per share) and the option to convert to common stock, but do not participate in dividends or liquidation distributions. They also have protective provisions against adverse changes to their rights.
• Potential Investors: The rebranding and potential for a higher stock price post-split might attract new investors, while the preferred stock structure could appeal to strategic partners seeking control.

Next Steps

• FINRA to complete processing of the name change to VitaNova Life Sciences Corporation.
• FINRA to complete processing of the 1-for-3 reverse stock split.
• The company to evaluate and select a new ticker symbol.
• The company to take corporate action to increase authorized common stock if needed for Series A Preferred Stock conversion.

Key Dates

Recommendation

The corporate rebranding and capital structure changes, including the reverse stock split and new preferred stock, represent significant strategic shifts. While the rebranding and increased authorized shares offer potential for future growth and flexibility, the reverse stock split often signals underlying challenges and can be viewed negatively by the market. The introduction of Series A Preferred Stock with substantial voting power, without dividend or liquidation preference, suggests a focus on control and strategic investment rather than broad shareholder returns. Given the pending FINRA approvals and the mixed implications of these actions, a 'hold' recommendation is appropriate until the market fully digests these changes and the company's new strategic direction becomes clearer, allowing for a more informed assessment of its long-term prospects and valuation.

Keywords

VitaNova Life Sciences Corporation, Yijia Group Corp., Reverse Stock Split, Preferred Stock, Series A Preferred Stock, Corporate Rebranding, SEC 8-K, Corporate Governance, Capital Structure, Voting Rights, Stock Conversion, Nevada Corporation